Is Vijaya Diagnostic Centre (VIJAYA) overvalued or fairly valued?

MarketChacha shows Vijaya Diagnostic Centre's valuation in context — a forward P/E of about 51.6, a price-to-book of about 15.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Vijaya Diagnostic Centre's revenue?

Vijaya Diagnostic Centre reported revenue of ₹765 Cr for FY2026, with net profit of ₹178 Cr, per official filings.

What is the share price of Vijaya Diagnostic Centre (VIJAYA)?

Vijaya Diagnostic Centre last traded at ₹1,428.20 (+2.6% on the day), as of 8/11/2026 — a delayed quote shown for education, not investment advice.

Vijaya Diagnostic Centre

VIJAYA · NSE · Healthcare · India

Snapshot

TickerVIJAYA

ExchangeNSE

SectorHealthcare

IndustryDiagnostics & Research

CountryIndia

HeadquartersHyderabad, India

Websitewww.vijayadiagnostic.com

Filings tracked6

About Vijaya Diagnostic Centre

Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. The company offers laboratory services, including clinical pathology, microbiology, haematology, serology, histopathology, cytogenetics, biochemistry, molecular diagnostics, CT scan, magnetic resonance imaging (MRI) scan, ultrasound, X-ray, cardiology, gastroenterology, nuclear medicine and PET/CT, and MRI-3T services. It also provides health checkups and home sample collection services. Vijaya Diagnostic Centre Limited was founded in 1981 and is based in Hyderabad, India.

Who owns it

Promoters53.5%
Institutions38.7%
Public & other7.8%

54 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend18.4% → 23.3%

Margin has expanded by about 4.9 points — the business is getting more profitable.

Growth qualityrev 19% · PAT 28%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (BSE (official results filing)). Education, not a rating or recommendation.

What's expected next

Next fiscal year

Rev ₹1,170 Cr · EPS 26.78

Est. earnings growth +23.0%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: BSE (official results filing)

Annual

Quarterly · last 5

Revenue (FY2026)

₹765 Cr

Net margin

23.3%

Revenue CAGR (3y)

+18.6%

Profit CAGR (3y)

+28.2%

EPS (FY2026)

17.33

Net profit (FY2026)

₹178 Cr

Ask MarketChacha about VIJAYA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2026	₹765 Cr	₹178 Cr	17.33	23.3%
FY2025	₹681 Cr	₹143 Cr	—	21.0%
FY2024	₹548 Cr	₹119 Cr	—	21.7%
FY2023	₹459 Cr	₹85 Cr	—	18.4%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	₹219 Cr	₹53 Cr	5.17	24.3%
2026Q1	₹206 Cr	₹53 Cr	5.12	25.5%
2025Q4	₹193 Cr	₹44 Cr	4.30	22.9%
2025Q3	₹202 Cr	₹43 Cr	—	21.5%
2025Q2	₹188 Cr	₹38 Cr	—	20.4%

Figures as reported, in ₹ (crore). Source: BSE (official results filing).

Filings & announcements

2026

Press Release / Media Release
Press Release on Q1 Un-audited financial results for FY 27
BSE8/6/2026
Investor Presentation
Investor Presentation on Un-audited results for the Quarter ended June 30, 2026
BSE8/6/2026
Press Release / Media Release
Press Release on Un-audited financial results for the quarter ended June 30, 2026
BSE8/6/2026
Un-Audited Financial Results For The Quarter Ended June 30, 2026
Un-audited financial results for the quarter ended June 30, 2026 on consolidated & Standalone basis
BSE8/6/2026
Board Meeting Outcome for Approval Of Un-Audited Financial Results For The Quarter Ended June 30, 2026
The Board of Directors in their meeting held on August 6, 2026 have approved the financial results for the quarter ended June 30, 2026
BSE8/6/2026
Board Meeting Intimation for Approval Of Un-Audit Financial Results For The Quarter Ended June 30, 2026
Vijaya Diagnostic Centre Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve Un-audit financial ....
BSE7/28/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.